E525 | Jean Schmitt (Jolt Capital ) & Rob Blackie (Crampton Blackie): The State of RNA in Europe & the TechBio Opportunity

In this week's podcast,  is joined by at and at to explore one of the most consequential deep tech opportunities Europe faces: RNA. With roots in foundational biology and applications from cancer therapy to precision agriculture, RNA is both a symbol and a stress test of Europe’s capacity to scale science into sovereignty.The conversation is based on their on the State of RNA in Europe, a data-rich, in-depth analysis of patents, funding flows, regulatory bottlenecks, and startup activity across the continent.Here’s what’s covered:03:05 The State of RNA in Europe05:59 Challenges in Commercialization and Investment09:09 The Landscape of RNA Companies in Europe15:02 Regulatory Challenges in RNA Development17:58 The Future of RNA in Europe26:54 Navigating Regulatory Challenges in Biocontrol Products30:46 The Impact of European Policies on Innovation32:41 Learning from Global Regulatory Practices40:34 The Exodus of Talent and Innovation from Europe45:59 Funding Challenges for RNA Companies in Europe

There are no comments yet.

Please log in to write the first comment.